Q4 2017 Earnings Estimate for BeiGene, Ltd. (BGNE) Issued By William Blair

BeiGene, Ltd. (NASDAQ:BGNE) – Stock analysts at William Blair issued their Q4 2017 earnings per share (EPS) estimates for BeiGene in a report issued on Tuesday. William Blair analyst Y. Xu forecasts that the company will post earnings of ($1.88) per share for the quarter. William Blair also issued estimates for BeiGene’s Q1 2018 earnings at ($2.11) EPS, Q2 2018 earnings at ($2.14) EPS, Q3 2018 earnings at ($2.18) EPS, Q4 2018 earnings at ($1.12) EPS and FY2018 earnings at ($7.56) EPS.

Several other equities research analysts have also issued reports on the stock. Maxim Group set a $120.00 price objective on shares of BeiGene and gave the company a “buy” rating in a research note on Tuesday. Cowen and Company reaffirmed a “buy” rating on shares of BeiGene in a research note on Tuesday. Robert W. Baird reaffirmed a “neutral” rating and issued a $83.00 price objective (up previously from $58.00) on shares of BeiGene in a research note on Tuesday. Zacks Investment Research lowered shares of BeiGene from a “hold” rating to a “sell” rating in a research note on Monday. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $95.00 price objective (up previously from $87.00) on shares of BeiGene in a research note on Friday, October 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. BeiGene presently has an average rating of “Buy” and a consensus price target of $96.67.

WARNING: This news story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/11/17/q4-2017-earnings-estimate-for-beigene-ltd-bgne-issued-by-william-blair.html.

BeiGene (NASDAQ:BGNE) traded down $0.51 during mid-day trading on Friday, hitting $84.18. 152,564 shares of the company traded hands, compared to its average volume of 191,624. The company has a debt-to-equity ratio of 0.57, a current ratio of 8.38 and a quick ratio of 8.38. BeiGene has a 1-year low of $26.43 and a 1-year high of $118.95.

BeiGene (NASDAQ:BGNE) last released its quarterly earnings data on Monday, November 13th. The company reported $2.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $2.31. The business had revenue of $220.21 million during the quarter, compared to analyst estimates of $1.55 million. During the same period in the previous year, the firm posted ($1.08) EPS.

Institutional investors and hedge funds have recently made changes to their positions in the company. Quantbot Technologies LP acquired a new position in shares of BeiGene during the third quarter valued at about $160,000. Teachers Retirement System of The State of Kentucky acquired a new position in shares of BeiGene during the third quarter valued at about $248,000. SG Americas Securities LLC acquired a new position in shares of BeiGene during the second quarter valued at about $111,000. Aperio Group LLC acquired a new position in shares of BeiGene during the third quarter valued at about $301,000. Finally, Jane Street Group LLC acquired a new position in shares of BeiGene during the third quarter valued at about $339,000. 52.09% of the stock is owned by institutional investors and hedge funds.

In other BeiGene news, CMO Amy C. Peterson sold 3,601 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $82.96, for a total transaction of $298,738.96. Following the completion of the transaction, the chief marketing officer now owns 1,201 shares of the company’s stock, valued at approximately $99,634.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO John Oyler sold 25,054 shares of the business’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $83.06, for a total transaction of $2,080,985.24. Following the transaction, the chief executive officer now directly owns 491,891 shares of the company’s stock, valued at approximately $40,856,466.46. The disclosure for this sale can be found here. In the last three months, insiders have sold 179,612 shares of company stock valued at $14,531,763. Company insiders own 19.90% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Earnings History and Estimates for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply